Shengyun Hu
- Cancer Research top 10%
- MicroRNA in disease regulation 5
- Immunology top 10%
- Immune cells in cancer 3
-
- Extracellular vesicles in disease 7
- Circular RNAs in diseases 5
- RNA modifications and cancer 2
-
- Cancer Immunotherapy and Biomarkers 6
- Peptidase Inhibition and Analysis 3
-
- Ferroptosis and cancer prognosis 2
- Co-authors
- Zhenqiang SunChengzeng WangYang LiuBingbing QiaoWeitang YuanMenghui ZhangLin LiuJinbo Liu
- Partner nations
- China
In The Last Decade
Shengyun Hu
19 papers receiving 889 citations
Hit Papers
Peers
Comparison fields: 5 of 74
- Cancer Research 308
- Immunology 271
- Molecular Biology 561
- Oncology 211
- Biomedical Engineering 145
Countries citing papers authored by Shengyun Hu
This map shows the geographic impact of Shengyun Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengyun Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengyun Hu more than expected).
Fields of papers citing papers by Shengyun Hu
This network shows the impact of papers produced by Shengyun Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengyun Hu. The network helps show where Shengyun Hu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shengyun Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 29 | |
| 4 | 2023 | 18 | |
| 5 | 2023 | 7 | |
| 6 | 2023 | 65 | |
| 7 | Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancersbreakdown → | 2023 | 216 |
| 8 | Engineered exosomes from different sources for cancer-targeted therapybreakdown → | 2023 | 292 |
| 9 | 2023 | 55 | |
| 10 | 2022 | 30 | |
| 11 | 2022 | 36 | |
| 12 | 2022 | 23 | |
| 13 | 2022 | 40 | |
| 14 | 2021 | 20 | |
| 15 | 2021 | 18 | |
| 16 | 2021 | 13 | |
| 17 | 2021 | 3 | |
| 18 | 2021 | 1 | |
| 19 | 2018 | 23 |
About Shengyun Hu
Shengyun Hu is a scholar working on Oncology, Cancer Research and Immunology, having authored 19 papers that have together received 895 indexed citations. Recurring topics across this work include Extracellular vesicles in disease (7 papers), Cancer Immunotherapy and Biomarkers (6 papers), MicroRNA in disease regulation (5 papers), Circular RNAs in diseases (5 papers), Peptidase Inhibition and Analysis (3 papers), Immune cells in cancer (3 papers), Ferroptosis and cancer prognosis (2 papers) and RNA modifications and cancer (2 papers). The work is most often cited by research in Cancer Research (308 citations), Immunology (271 citations) and Molecular Biology (561 citations). Shengyun Hu has collaborated with scholars based in China. Frequent co-authors include Zhenqiang Sun, Chengzeng Wang, Yang Liu, Bingbing Qiao, Weitang Yuan, Menghui Zhang, Lin Liu, Jinbo Liu, Lin Liu and Hao Zhang. Their work appears in journals such as Oncogene, Frontiers in Immunology and Molecular Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.